Chairman, General Manager, Professor of Oncology, Academician of the Chinese Academy of Sciences, former Vice President of Sichuan University, Director of the Clinical Oncology Center and Director of the State Key Laboratory of Biotherapy, West China Hospital, Chairman of the Chinese Medical Biotechnology Association, Head of the National Biotherapy Collaborative Innovation Center, National Comprehensive Head of the technology platform for new drug research and development, chief scientist of the "973" project of the Ministry of Science and Technology, head of the National Natural Science Foundation of China Innovative Research Group, co-editor of Signal Transduction and Targeted Therapy, associate editor of Human Gene Therapy, associate editor of Current Molecular Medicine, Current Cancer Drug Targets. He is responsible for the editorial board of the Asian region, and the editorial board of Scientific Reports and other international magazines. The second batch of specially-appointed professors in the "Major Talents Program" of the Ministry of Education, winner of the National Science Fund for Distinguished Young Scholars in 1997, candidates for the first and second levels of the National "One Hundred Thousand Talents Project", and the 15th "863" Bioengineering in the field of biology and agricultural technology, Leader of the technical subject expert group, member of the 12th Five-Year "863" biotechnology drug subject expert group in the field of biology and medicine, former vice president of the Chinese Medical Association, former executive deputy director of the Department of Biomedicine of the Science and Technology Committee of the Ministry of Education.
Executive Deputy General Manager, Doctor of Clinical Medicine, Professor of State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Ph.D. supervisor, Director of Laboratory of Genetic Engineering Antibody Research, Outstanding Contribution Expert in Sichuan Province, Deputy Director of Targeted Therapy Sub-committee of Sichuan Cancer Society, Member of Translational Medicine Sub-committee, Chinese Research Hospital Association. His research interests include antibody drug development, tumor immunogene therapy, tumor cell biology, and synthetic biology. As the project leader, he undertook more than 20 national, provincial and enterprise horizontal projects. He has published more than 100 scientific papers and obtained more than 10 authorized patents. He has developed many innovative antibody drugs, which have been transferred to enterprises or developed in cooperation with enterprises.
Executive Deputy General Manager, Ph.D., Researcher, Ph.D. supervisor. Currently working at the State Key Laboratory of Biotherapy/Biotherapy Collaborative Innovation Center/National Comprehensive New Drug Research and Development Platform, Director of the Immunogene Cell Therapy Office, West China Hospital of Sichuan University; Editor of Gene Therapy and PloS one magazine.
Deputy General Manager, Ph.D., Researcher/Ph.D. supervisor at State Key Laboratory of Biotherapy, West China Hospital of Sichuan University. Winner of the New Century Excellent Talents Program of the Ministry of Education (2009); Winner of the Sichuan Outstanding Youth Academic and Technological Leader Funding Program (2012); Leading Talent of National High-level Talent Special Support Program (2014); National "Ten Thousand Talents Program" Leader (2016); Leading Talent of Health and Family Planning in Sichuan Province (2017); Leading Talent of Tianfu Innovation in the "Tianfu Ten Thousand Talents Program" of Sichuan Province (2018). Current deputy secretary general of China Medical Biotechnology Association.
Deputy General Manager, Doctor of Clinical Medicine. Ph.D. supervisor/Researcher of State Key Laboratory of Biotherapy, Sichuan University. Visiting Professor, Department of Microbiology, University of Washington School of Medicine (2014-2015). She has been engaged in the research and development of new drugs against resistant microorganisms and vaccines against resistant microorganisms for many years, and is responsible for the clinical trials of WestVac’s vaccine project in China and abroad. She has been responsible for a number of national and provincial projects, participated in 2 NIH projects, published more than 30 SCI papers and applied for more than 10 invention patents.
Deputy General Manager, Doctor of Cell Biology, Senior Engineer, 2013 "Double Hundred Plan" Innovation Talent of Yantai, Shandong Province, years of experience in the R&D of innovative biological medicines, mainly specializing in the R&D and production of viral vaccines and tumor immunological preparations.
Deputy General Manager, Ph.D., Researcher, Ph.D. supervisor. Visiting scholar, University of Michigan, USA. WuXi AppTec Life Chemistry Research Fellowship. Outstanding Youth Academic Technology Leader of Sichuan Province. She has published more than 80 SCI papers in international academic journals. She has undertaken more than ten national and enterprise cooperation projects, such as national "863" and National Natural Science Foundation of China. Application and authorization of a number of national invention patents and international PCT patents. She has rich experience in biotechnology, leading the team to support the process development, structural characterization, quality standard establishment, toxicological batch and clinical trial sample preparation, process scale-up to commercial production, and CMC work including registration and application for recombinant products.
Ph.D., Professor/Researcher/Ph.D. supervisor at the State Key Laboratory of Biotherapy, Sichuan University. His research mainly focuses on pathogen-host interaction and new antiviral strategies, explores the pathogen invasion process through structural biology and other methods, and provides a basis for finding effective antiviral inhibitor molecules (small molecule compounds, antibodies, etc.). He has published more than 60 SCI papers in international academic journals.
Ph.D., Associate Researcher. His main research areas are disease target screening, tumor biotherapy, and recombinant protein drug R&D. He has presided over the "863" project and a number of National Natural Science Foundation of China (NSFC) projects. He has published more than 50 SCI papers in international academic journals such as Cell Res., STTT, J. Immunol., Nat. cell biol., and participated in the application of 2 national invention patents.
MD., Major in Biotherapy of major human diseases at the State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, focusing on tumor cell biology, tumor vaccine, tumor immunogenic therapy, and recombinant protein drug research and development. He published a research paper A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity in Nature as the first author, and more than 10 SCI research papers in Signal Transduct Target Therapy, Nanotoday, Theranostics, EBiomedicine, iScience, ACS Appl Mater Interinterfaces and other journals.